Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Veloxis Pharmaceuticals A/S Maintains FY 2013 Earnings Guidance-Reuters


Thursday, 22 Aug 2013 01:12am EDT 

Reuters reported that Veloxis Pharmaceuticals A/S has maintained its outlook with an operating and net loss in a range of between DKK 170 million and DKK 200 million for fiscal year 2013. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2013 operating profit (EBIT) of negative DKK 188.50 million and net income of negative DKK 183.50 million.